Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
Janssen,Bruton tyrosine kinase inhibitor (BTKi),"Chronic lymphocytic leukaemia (CLL), first-line, without TP53 mutation",Bruton tyrosine kinase inhibitor (BTKi),Options for investment,Community and Hospital,Oncology Agents and Immunosuppressants
